Dementia, Clinical Research, Alzheimer's disease, Lewy Body, Neurodegenerative, Research, Dementia Research, DeNDRoN Dementias Clinical Studies Group
Dementias CSG
Chair: Professor Cornelius Katona, University College LondonIt is estimated that 1 person out of 20 will develop dementia, and there is no way of predicting who will be affected. While there are treatments available, it is clear that we need to do more to develop new, and better, treatments. Working in collaboration with existing research activity, the Dementias Clinical Studies Group (CSG) has set itself several roles, and is geared towards bringing together expertise and enthusiasm in order to establish an authoritative voice in the research community. From the first we have taken the view that patient and public involvement is vital to the success of the group, and are establishing patient and carer representatives as equal members within it.
Dementias CSG roles:
-
Actively engaging with studies within the Group’s portfolio
-
Identifying existing high quality studies that should be adopted by DeNDRoN
-
Generating ideas for new studies
-
Contributing to the development of high quality applications
-
Contributing to the Group’s annual report and peer-review of the portfolio
-
Providing expert advice
The CSG is also tasked with reviewing existing research/opportunities including the Cochrane collaboration, the MHRN scoping exercise and the UK dementia guidelines. We will also be actively engaging with pertinent issues, and have initiated 31 projects across priority categories including patient and carer experience and quality of care and services, new technologies, diagnosis, treatment of cognitive symptoms, treatment of psychiatric symptoms and behavioural problems, and the prevention of comorbidities.
The CSG is planning to be actively involved in collaborative activity. It took a lead role in a May 2007 workshop focusing on in the prevention, prophylaxis and treatment of cognitive impairment after stroke and other cerebrovascular disease, in conjunction with the MHRN and the Alzheimer’s Society. A taskforce has been convened by DeNDRoN and the Alzheimer’s Society with two themes - Assistive Technology and End of Life Care in Dementia.
More information about the task force is available here.
Report from Ministerial Summit on Dementia Research